Abstract

Squamous cell carcinomas (SCCs) account for the majority of cancer mortalities. Although TP63 is an established lineage-survival oncogene in SCCs, therapeutic strategies have not been developed to target TP63 or it's downstream effectors. In this study we demonstrate that TP63 directly regulates NRG1 expression in human SCC cell lines and that NRG1 is a critical component of the TP63 transcriptional program. Notably, we show that squamous tumors are dependent NRG1 signaling in vivo, in both genetically engineered mouse models and human xenograft models, and demonstrate that inhibition of NRG1 induces keratinization and terminal squamous differentiation of tumor cells, blocking proliferation and inhibiting tumor growth. Together, our findings identify a lineage-specific function of NRG1 in SCCs of diverse anatomic origin.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data file has been provided for Figure 4.

Article and author information

Author details

  1. Ganapati V Hegde

    Discovery Oncology, Genentech Inc, South San Francisco, United States
    For correspondence
    gvhegde@gmail.com
    Competing interests
    Ganapati V Hegde, employee of Genentech Inc at the time of participation in this study.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6473-153X
  2. Cecile de la Cruz

    Translational Oncology, Genentech Inc, South San Francisco, United States
    Competing interests
    Cecile de la Cruz, employee of Genentech Inc at the time of participation in this study.
  3. Jennifer M Giltnane

    Department of Pathology, Genentech Inc, South San Francisco, United States
    Competing interests
    Jennifer M Giltnane, employee of Genentech Inc at the time of participation in this study.
  4. Lisa Crocker

    Translational Oncology, Genentech Inc, South San Francisco, United States
    Competing interests
    Lisa Crocker, employee of Genentech Inc at the time of participation in this study.
  5. Avinashnarayan Venkatanarayan

    Discovery Oncology, Genentech Inc, South San Francisco, United States
    Competing interests
    Avinashnarayan Venkatanarayan, employee of Genentech Inc at the time of participation in this study.
  6. Gabriele Schaefer

    Translational Oncology, Genentech Inc, South San Francisco, United States
    Competing interests
    Gabriele Schaefer, employee of Genentech Inc at the time of participation in this study.
  7. Debra Dunlap

    Pathology, Genentech Inc, South San Francisco, United States
    Competing interests
    Debra Dunlap, employee of Genentech Inc at the time of participation in this study.
  8. Joerg D Hoeck

    Molecular Oncology, Genentech Inc, South San Francisco, United States
    Competing interests
    Joerg D Hoeck, employee of Genentech Inc at the time of participation in this study.
  9. Robert Piskol

    Bioinformatics, Genentech Inc, South San Francisco, United States
    Competing interests
    Robert Piskol, employee of Genentech Inc at the time of participation in this study.
  10. Florian Gnad

    Bioinformatics, Genentech Inc, South San Francisco, United States
    Competing interests
    Florian Gnad, employee of Genentech Inc at the time of participation in this study.
  11. Zora Modrusan

    Department of Molecular Biology, Genentech Inc, South San Francisco, United States
    Competing interests
    Zora Modrusan, employee of Genentech Inc at the time of participation in this study.
  12. Frederic J de Sauvage

    Department of Molecular Biology, Genentech Inc, South San Francisco, United States
    Competing interests
    Frederic J de Sauvage, employee of Genentech Inc at the time of participation in this study.
  13. Christian W Siebel

    Discovery Oncology, Genentech Inc, South San Francisco, United States
    Competing interests
    Christian W Siebel, employee of Genentech Inc at the time of participation in this study.
  14. Erica L Jackson

    Discovery Oncology, Genentech Inc, South San Francisco, United States
    For correspondence
    ericajackso@gmail.com
    Competing interests
    Erica L Jackson, employee of Genentech Inc at the time of participation in this study.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7100-8021

Funding

The authors declare that there was no funding for this work

Ethics

Animal experimentation: All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) at Genentech. The animal studies included herein were performed based on approved IACUC protocol numbers (LASAR 10-2319A, 16-1304, 16-1304A, 16-0098, 16-1120, 16-1143 and 16-2005, 16-1120).

Copyright

© 2019, Hegde et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,593
    views
  • 363
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ganapati V Hegde
  2. Cecile de la Cruz
  3. Jennifer M Giltnane
  4. Lisa Crocker
  5. Avinashnarayan Venkatanarayan
  6. Gabriele Schaefer
  7. Debra Dunlap
  8. Joerg D Hoeck
  9. Robert Piskol
  10. Florian Gnad
  11. Zora Modrusan
  12. Frederic J de Sauvage
  13. Christian W Siebel
  14. Erica L Jackson
(2019)
NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma
eLife 8:e46551.
https://doi.org/10.7554/eLife.46551

Share this article

https://doi.org/10.7554/eLife.46551

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    Yang Peng, Jing Yang ... Liang Weng
    Research Article

    Background:

    Cervical adenocarcinoma (ADC) is more aggressive compared to other types of cervical cancer (CC), such as squamous cell carcinoma (SCC). The tumor immune microenvironment (TIME) and tumor heterogeneity are recognized as pivotal factors in cancer progression and therapy. However, the disparities in TIME and heterogeneity between ADC and SCC are poorly understood.

    Methods:

    We performed single-cell RNA sequencing on 11 samples of ADC tumor tissues, with other 4 SCC samples served as controls. The immunochemistry and multiplexed immunofluorescence were conducted to validate our findings.

    Results:

    Compared to SCC, ADC exhibited unique enrichments in several sub-clusters of epithelial cells with elevated stemness and hyper-malignant features, including the Epi_10_CYSTM1 cluster. ADC displayed a highly immunosuppressive environment characterized by the enrichment of regulatory T cells (Tregs) and tumor-promoting neutrophils. The Epi_10_CYSTM1 cluster recruits Tregs via ALCAM-CD6 signaling, while Tregs reciprocally induce stemness in the Epi_10_CYSTM1 cluster through TGFβ signaling. Importantly, our study revealed that the Epi_10_CYSTM1 cluster could serve as a valuable predictor of lymph node metastasis for CC patients.

    Conclusions:

    This study highlights the significance of ADC-specific cell clusters in establishing a highly immunosuppressive microenvironment, ultimately contributing to the heightened aggressiveness and poorer prognosis of ADC compared to SCC.

    Funding:

    Funded by the National Natural Science Foundation of China (82002753; 82072882; 81500475) and the Natural Science Foundation of Hunan Province (2021JJ40324; 2022JJ70103).